Overview

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Status:
Terminated

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Fludarabine
Fludarabine phosphate